Lexicon Pharmaceuticals Income Statement (2010-2025) | LXRX

Income Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Revenue & cost
Revenue (Quarter)
1.25M0.46M0.35M0.13M1.65M1.75M1.47M28.87M14.18M-39.66M
Cost of Revenue (Quarter)
0.17M0.07M0.03M0.01M
Gross Profit (Quarter)
1.48M1.68M28.83M14.17M
Operating items
Research & Development (Quarter)
18.25M20.14M19.66M28.11M12.03M14.54M17.56M14.76M14.37M17.64M25.78M26.68M15.30M15.75M18.76M11.31M
Selling, General & Administrative (Quarter)
3.86M4.53M4.05M4.01M19.14M30.01M32.23M32.61M32.06M39.19M39.59M32.26M11.61M9.35M7.60M8.76M
Restructuring Costs (Quarter)
1.56M1.80M2.34M1.57M
Other Operating Expenses (Quarter)
0.17M0.07M0.03M0.01M
Operating Expenses (Quarter)
23.68M26.48M26.05M33.69M31.17M44.55M49.79M47.37M46.43M57.00M65.44M58.94M26.91M25.13M26.37M20.07M
Operating Income (Quarter)
-22.43M-25.93M-25.69M-33.34M-55.35M-63.69M3.74M-12.19M
EBIT (Quarter)
-22.43M-25.93M-25.69M-33.34M-55.35M-63.69M3.74M-12.19M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)
0.05M0.07M0.06M0.04M
Other Non Operating Income (Quarter)
0.00M0.03M0.09M0.01M4.14M3.44M1.83M1.57M
Non Operating Income (Quarter)
0.00M0.03M0.09M0.01M4.14M4.56M2.32M1.57M
Net income details
EBT (Quarter)
-23.00M-26.67M-26.10M-33.84M-55.35M-63.69M3.74M-12.19M
Tax Provisions (Quarter)
Profit After Tax (Quarter)
-23.00M-26.64M-26.10M-33.84M-48.40M-53.43M-64.81M-25.30M3.25M-12.77M
Income from Continuing Operations (Quarter)
-23.00M-26.67M-26.10M-33.84M-55.35M-63.69M3.74M-12.19M
Consolidated Net Income (Quarter)
-23.00M-26.67M-26.10M-33.84M-55.35M-63.69M3.74M-12.19M
Income towards Parent Company (Quarter)
-23.00M-26.67M-26.10M-33.84M-55.35M-63.69M3.74M-12.19M
Net Income towards Common Stockholders (Quarter)
-23.00M-26.67M-26.10M-33.84M-55.35M-63.69M3.74M-12.19M
Additional items
EPS (Basic) (Quarter)
-0.07-0.08-0.08-0.10-0.17-0.180.01-0.04
EPS (Weighted Average and Diluted) (Quarter)
-0.17-0.180.01-0.04
Shares Outstanding (Weighted Average) (Quarter)
302.84M337.53M337.67M337.68M340.76M480.32M480.63M490.05M189.01M0.18M244.93M221.13M245.39M278.11M361.49M320.03M362.07M363.29M362.93M363.05M
Shares Outstanding (Diluted Average) (Quarter)
310.84M306.11M362.69M362.93M
EBITDA (Quarter)
-22.43M-25.93M-25.69M-33.34M-53.57M-64.27M3.21M-12.73M
Interest Expenses (Quarter)
0.63M0.81M0.56M0.55M
Tax Rate (Quarter)